Board of Directors

Jörgen Olsson
Jörgen Olsson
Chairman of the Board since March 2019.

Born: 1961
Share holdings:

Education: Bachelor of Science in Business and Economics, Luleå University.
Previous experience: President and CEO of Hoist Finance 2012-2018, Head of Corporate Banking at Kaupthing Bank Sweden, senior positions at SEB / Enskilda Corporate and Group Treasurer at Elekta. Member of the Board of Hoist Finance 2010-2018.
Other assignments: –

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Sven Rohmann
Sven Rohmann
Member of the Board since March 2019.

Born: 1962
Share holdings:

Education: MD Johannes Gutenberg University, PhD Erasmus University and MBA European Business School and Kellogg’s University.
Previous experience:CMO for Immudyne Inc, CEO of Adiuvo Investments SA, General Manager Europe for healthcare venture fund Burrill & Co, Vice President Biotec Pharmacon ASA, venture capital fund manager for Novartis Pharma AG, Managing Partner for Nextech Venture, Switzerland, CEO of BioVision AG, CEO of Ganymed Pharmaceuticals AG, and globally responsible for oncology for Merck Serono.
Selected Board assignments: Chairman of Helix Biopharma Corp., ImVision GmbH & Inc.
Other assignments: Advisor and Chief Business Development Officer to Oryx GmbH (translational medicine) and Center for Molecular Medicine, KI and TCER AB.

Not independent in relation to Oasmia and the company management, independent in relation to major shareholders of the company.

Peter Zonabend
Peter Zonabend
Member of the Board since March 2019.

Born: 1980
Share holdings: 0 shares. Manages 79,917 shares by proxy.

Education: LL.M from Stockholm University, EMLE from Erasmus School of Law, Bsc in Business and Economics from Stockholm University and DU EAED from Aix Marseille Université.
Previous experience: CEO of Victoria Investments Holding Ltd, 2010-2017, Law Firm Fylgia, Law Firm Björn Rosengren.
Selected Board assignments: Hövding Sverige AB, HQ AB, TCER AB, CBD Solutions AB.
Other ongoing assignments: CEO Arwidsro, board assignment within Arwidsro.

Independent in relation to Oasmia and company management, not independent of major shareholders in the company.

Gunilla Öhman
Gunilla Öhman
Member of the Board since March 2019.

Born: 1959
Share holdings:

Education: MSc in Business and Economics from Stockholm School of Economics.
Previous experience: Director of Communications at SEB Group, Riksbank and Bankstödsnämnden. Prior to that, Swedish Match for 8 years and financial journalist at Veckans Affärer and SVT. Communications advisor since 15 years. IR manager for hire for companies listing or listed, most recently Elekta.

Board assignments in Hoist Finance from 2014 to 2019, earlier in Proffice 9 years, HMS Networks 5 years, SJ 5 years, AMF Funds 9 years, Oatly 5 years. Participation and leadership of Audit Committees in several of the companies.

Other ongoing assignments: IR Manager at NCAB and Board member of Atvexa.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Hege Hellström
Member of the Board since September 2019.

Born: 1965
Share holdings:

Education: B.A. in Bio-engineering from Ullevaal School of Bioengineering in Oslo.
Previous experience: Hege has worked at the biotechnology company Sobi since 2013 and was president for EMENAR (Europe, Middle East, North Africa and Russia). Prior to that, she was globally responsible for the Cardiovascular business area within Sanofi, VP Renal Europe and Head of Regional Liaisons at Sanofi, VP Renal and Endocrine Europe at Genzyme and General Manager Benelux at Genzyme. Before Genzyme, she was 13 years at Baxter.

Independent in relation to Oasmia, the company management and to major shareholders of the company.

Anders Härfstrand
Member of the Board since September 2019.

Born: 1956
Share holdings:

Education: MD and Ph.D from Karolinska Institutet in Stockholm.
Previous experience: Anders has been an advisor within the pharmaceutical industry since 2015 and a board member of both private and listed companies in the sector (present NASDAQ-listed Prothena). Prior to that, he has held leading positions in a number of successful biotechnology companies and has long experience in building global commercial operations with billion-dollar turnover, driving organic growth, restructuring and mergers. He has been CEO of a number of companies, including Nitec Pharma AG, Humabs Biomed SA, ADAMA AGRO (CHEM CHINA) and BBB Therapeutics. Before that, he held leading world wide roles within Serono, Pfizer and Pharmacia.
Ongoing Board assignments: Prothena

Independent in relation to Oasmia, the company management and to major shareholders of the company.